Table 1 Characteristics of participants by COVID-19 severity
From: SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection
No./total No. (%) or median (IQR) | Pa | |||
|---|---|---|---|---|
Overall (n = 121) | Non-severe (n = 102) | Severe (n = 19) | ||
Demographic characteristics | ||||
Age, years | 49 (40–57) | 48.5 (39–57) | 56 (46–59) | 0.109 |
<30 | 6 (5) | 6 (5.9) | 0 (0) | 0.588 |
>60 | 14 (11.6) | 11 (10.8) | 3 (15.8) | 0.460 |
Female | 71 (58.7) | 63 (61.8) | 8 (42.1) | 0.132 |
Body mass index | 23.9 (22.5–25.6) | 23.9 (22.6–25.4) | 24.2 (21.9–26) | 0.859 |
Comorbidity | 37 (30.6) | 29 (28.4) | 8 (42.1) | 0.280 |
Hypertension | 31 (25.6) | 26 (25.5) | 5 (26.3) | 1.00 |
Diabetes | 8 (6.6) | 6 (5.9) | 2 (10.5) | 0.610 |
Autoimmune diseases | 2 (1.7) | 1 (1) | 1 (5.3) | 0.290 |
Cardiovascular diseases | 3 (2.5) | 3 (2.9) | 0 (0) | 1.00 |
Cancer | 1 (0.8) | 1 (1) | 0 (0) | 1.00 |
Last follow-up findings | ||||
Symptom onset to last follow-up, days | 348 (344–351) | 348 (344–351) | 347 (339–351) | 0.592 |
Discharge to last follow-up, days | 316 (311–321) | 317 (312–323) | 312 (300–314) | <.001 |
Persistent COVID-19-related symptoms | 36 (29.8) | 21 (20.6) | 15 (78.9) | <.001 |
Respiratory symptoms | 22 (18.2) | 10 (9.8) | 12 (63.2) | <.001 |
Neurological/mental symptoms | 15 (12.4) | 9 (8.8) | 6 (31.6) | 0.014 |
Fatigue/weakness | 14 (11.6) | 7 (6.9) | 7 (36.8) | 0.001 |
Other disease diagnosis after discharge | 12 (9.9) | 9 (8.8) | 3 (15.8) | 0.400 |
SARS-CoV-2 PCR-positive after discharge | 5 (4.1) | 5 (4.9) | 0 (0) | 1.00 |
Anti-SARS-CoV-2 IgM positive | 2 (1.7) | 2 (2) | 0 (0) | 0.583 |
Weakly positive | 3 (2.5) | 2 (2) | 1 (5.3) | |
Negative | 116 (95.9) | 98 (96.1) | 18 (94.7) | |
Anti-SARS-CoV-2 IgG positive | 55 (45.5) | 42 (41.2) | 13 (68.4) | 0.062 |
Weakly positive | 20 (16.5) | 17 (16.7) | 3 (15.8) | |
Negative | 46 (38) | 43 (42.2) | 3 (15.8) | |
Abnormal CT findings at prior follow-ups | 21/62 (33.9) | 12/48 (25) | 9/14 (64.3) | 0.010 |
Abnormal CT findings at last follow-up | 10 (8.3) | 0 (0) | 10 (52.6) | <.001 |
